Lenacapavir: A Novel, Potent, and Selective First-in-Class Inhibitor of HIV-1 Capsid Function Exhibits Optimal Pharmacokinetic Properties for a Long-Acting Injectable Antiretroviral AgentRaju Subramanian, Bill J. Smith, M. Naveed Shaik et al.|Molecular Pharmaceutics|2023Cited by 52
Lenacapavir Exhibits Atropisomerism—Mechanistic Pharmacokinetics and Disposition Studies of Lenacapavir Reveal Intestinal Excretion as a Major Clearance PathwayJim Zheng, Raju Subramanian, Bing Lu et al.|Journal of Pharmacology and Experimental Therapeutics|2024Cited by 13
Discovery ofLenacapavir: First-in-Class Twice-YearlyCapsid Inhibitor for HIV-1 Treatment and Pre-exposure ProphylaxisEda Canales, John O. Link, Winston C. Tse et al.|Journal of Medicinal Chemistry|2025Cited by 11
Human and nonclinical disposition of [<sup>14</sup>C]bictegravir, a potent integrase strand-transfer inhibitor for the treatment of HIV-1 infectionRaju Subramanian, Bill J. Smith, John Ling et al.|Xenobiotica|2022Cited by 7
Human pharmacokinetics prediction with an <i>in vitro</i>–<i>in vivo</i> correction factor approach and <i>in vitro</i> drug-drug interaction profile of bictegravir, a potent integrase-strand transfer inhibitor component in approved biktarvy<sup>®</sup> for the treatment of HIV-1 infectionRaju Subramanian, Bill J. Smith, Jianhong Wang et al.|Xenobiotica|2022Cited by 5